AR077221A1 - {5-[4-(3,3-dimetil-azetidina-1-carbonil)-fenil]-[1,2,4]triazolo[1,5-a]piridin-2-il} amida del acido ciclopropanocarboxilico inhibidor de quinasas janus(jak), en particular jak1, composiciones farmaceuticas que lo contienen y uso de los mismos para tratar afecciones inflamatorias, autoinmunes y proli - Google Patents
{5-[4-(3,3-dimetil-azetidina-1-carbonil)-fenil]-[1,2,4]triazolo[1,5-a]piridin-2-il} amida del acido ciclopropanocarboxilico inhibidor de quinasas janus(jak), en particular jak1, composiciones farmaceuticas que lo contienen y uso de los mismos para tratar afecciones inflamatorias, autoinmunes y proliInfo
- Publication number
- AR077221A1 AR077221A1 ARP100102236A ARP100102236A AR077221A1 AR 077221 A1 AR077221 A1 AR 077221A1 AR P100102236 A ARP100102236 A AR P100102236A AR P100102236 A ARP100102236 A AR P100102236A AR 077221 A1 AR077221 A1 AR 077221A1
- Authority
- AR
- Argentina
- Prior art keywords
- quanasas
- autoinmune
- piridin
- proli
- affections
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 101000997835 Homo sapiens Tyrosine-protein kinase JAK1 Proteins 0.000 title 1
- 102000042838 JAK family Human genes 0.000 title 1
- 108091082332 JAK family Proteins 0.000 title 1
- 102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 title 1
- 239000002253 acid Substances 0.000 title 1
- 230000002757 inflammatory effect Effects 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 201000010099 disease Diseases 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 210000000845 cartilage Anatomy 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 206010010356 Congenital anomaly Diseases 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 206010052779 Transplant rejections Diseases 0.000 abstract 1
- 230000006866 deterioration Effects 0.000 abstract 1
- 230000004968 inflammatory condition Effects 0.000 abstract 1
- 230000036244 malformation Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000007306 turnover Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Abstract
Este compuesto puede prepararse como una composicion farmacéutica, y puede usarse para la prevencion y el tratamiento de una diversidad de afecciones en mamíferos, que incluyen humanos, que abarcan, a modo de ejemplo, sin limitacion, afecciones inflamatorias, enfermedades autoinmunitarias, enfermedades proliferativas, rechazo de trasplantes, enfermedades que involucran el deterioro del recambio de cartílago, malformaciones congénitas del cartílago y enfermedades asociadas con la hipersecrecion de IL6. Reivindicacion 1: Un compuesto de acuerdo con la formula (1) o una de sus sales farmacéuticamente aceptables.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22068509P | 2009-06-26 | 2009-06-26 | |
| US29818810P | 2010-01-25 | 2010-01-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR077221A1 true AR077221A1 (es) | 2011-08-10 |
Family
ID=42340530
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100102236A AR077221A1 (es) | 2009-06-26 | 2010-06-24 | {5-[4-(3,3-dimetil-azetidina-1-carbonil)-fenil]-[1,2,4]triazolo[1,5-a]piridin-2-il} amida del acido ciclopropanocarboxilico inhibidor de quinasas janus(jak), en particular jak1, composiciones farmaceuticas que lo contienen y uso de los mismos para tratar afecciones inflamatorias, autoinmunes y proli |
Country Status (37)
| Country | Link |
|---|---|
| US (2) | US8796457B2 (es) |
| EP (2) | EP2792677B1 (es) |
| JP (1) | JP5486084B2 (es) |
| KR (1) | KR101712561B1 (es) |
| CN (1) | CN102459261B (es) |
| AR (1) | AR077221A1 (es) |
| AU (1) | AU2010264635B2 (es) |
| BR (1) | BRPI1014759A2 (es) |
| CA (1) | CA2765988C (es) |
| CL (1) | CL2011003276A1 (es) |
| CO (1) | CO6491039A2 (es) |
| CR (1) | CR20110673A (es) |
| CY (1) | CY1119711T1 (es) |
| DK (2) | DK2445912T3 (es) |
| DO (1) | DOP2011000378A (es) |
| EA (1) | EA020111B1 (es) |
| ES (2) | ES2519170T3 (es) |
| HR (2) | HRP20141057T1 (es) |
| HU (1) | HUE034205T2 (es) |
| IL (1) | IL216618A (es) |
| JO (1) | JO3030B1 (es) |
| LT (1) | LT2792677T (es) |
| MA (1) | MA33447B1 (es) |
| ME (1) | ME01916B (es) |
| MX (1) | MX2011013451A (es) |
| NZ (1) | NZ596836A (es) |
| PE (1) | PE20120494A1 (es) |
| PL (2) | PL2445912T3 (es) |
| PT (2) | PT2445912E (es) |
| RS (1) | RS53617B1 (es) |
| SG (1) | SG177359A1 (es) |
| SI (2) | SI2792677T1 (es) |
| SM (2) | SMT201700333T1 (es) |
| TW (1) | TWI469981B (es) |
| UY (1) | UY32741A (es) |
| WO (1) | WO2010149771A1 (es) |
| ZA (1) | ZA201109502B (es) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3041B1 (ar) | 2008-07-25 | 2016-09-05 | Galapagos Nv | مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية |
| TWI462920B (zh) | 2009-06-26 | 2014-12-01 | 葛萊伯格有限公司 | 用於治療退化性及發炎疾病之新穎化合物 |
| JO3030B1 (ar) | 2009-06-26 | 2016-09-05 | Galapagos Nv | مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات |
| JO3417B1 (ar) | 2010-01-08 | 2019-10-20 | Regeneron Pharma | الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r |
| WO2012142160A1 (en) * | 2011-04-12 | 2012-10-18 | Rigel Pharmaceuticals, Inc. | Methods for inhibiting allograft rejection |
| SG10201914052TA (en) * | 2011-10-11 | 2020-03-30 | Sanofi Biotechnology | Compositions for the treatment of rheumatoid arthritis and methods of using same |
| TWI589299B (zh) | 2011-10-11 | 2017-07-01 | 再生元醫藥公司 | 用於治療類風濕性關節炎之組成物及其使用方法 |
| PE20150187A1 (es) * | 2012-06-22 | 2015-02-27 | Galapagos Nv | Aminotriazolopiridina para uso en tratamiento de inflamacion y composiciones farmaceuticas de la misma |
| CN105745209B (zh) | 2013-09-05 | 2018-10-23 | 豪夫迈·罗氏有限公司 | 三唑并吡啶化合物、组合物及其使用方法 |
| EP3318565B1 (en) | 2013-12-05 | 2021-04-14 | Pfizer Inc. | Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides |
| GB201402071D0 (en) | 2014-02-07 | 2014-03-26 | Galapagos Nv | Novel salts and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
| GB201402070D0 (en) | 2014-02-07 | 2014-03-26 | Galapagos Nv | Pharmaceutical compositions for the treatment of inflammatory disorders |
| KR102747428B1 (ko) * | 2015-04-13 | 2024-12-27 | 알파시그마 에스.피.에이. | 심혈관 질환의 치료 방법 |
| US11414413B2 (en) | 2016-07-26 | 2022-08-16 | Suzhou Longbiotech Pharmaceuticals Co., Ltd. | Heterocyclic compound as JAK inhibitor, and salts and therapeutic use thereof |
| US11427581B2 (en) | 2018-01-31 | 2022-08-30 | Zhuhai United Laboratories Co., Ltd. | JAK inhibitor and use thereof |
| MX2021002422A (es) | 2018-08-29 | 2021-07-15 | Regeneron Pharma | Métodos y composiciones para el tratamiento de sujetos que padecen artritis reumatoide. |
| TW202521583A (zh) | 2019-01-31 | 2025-06-01 | 法商賽諾菲生物技術公司 | 用於治療幼年原發性關節炎之組成物及方法 |
| CA3137909A1 (en) | 2019-04-24 | 2020-10-29 | Sanofi Biotechnology | Methods of diagnosis and treatment of rheumatoid arthritis |
| US12297279B2 (en) | 2019-06-04 | 2025-05-13 | Sanofi Biotechnology | Compositions and methods for treating pain in subjects with rheumatoid arthritis |
| CN111072655B (zh) * | 2019-12-30 | 2021-12-10 | 深圳市坤健创新药物研究院 | 一种三氮唑并吡啶类化合物及其制备方法和药用组合物与应用 |
| AU2021276656A1 (en) | 2020-05-19 | 2022-11-24 | Cybin Irl Limited | Deuterated tryptamine derivatives and methods of use |
| US11596612B1 (en) | 2022-03-08 | 2023-03-07 | PTC Innovations, LLC | Topical anesthetics |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60016384T2 (de) | 1999-01-29 | 2005-12-01 | Chugai Seiyaku K.K. | Chondrogonese promotoren und indolin-2-on derivate |
| EP1391211A1 (en) | 2001-04-27 | 2004-02-25 | Chugai Seiyaku Kabushiki Kaisha | Chondrogenesis promoters |
| US6514989B1 (en) * | 2001-07-20 | 2003-02-04 | Hoffmann-La Roche Inc. | Aromatic and heteroaromatic substituted 1,2,4-triazolo pyridine derivatives |
| CA2487679A1 (en) * | 2002-05-30 | 2003-12-11 | Vertex Pharmaceuticals Incorporated | Inhibitors of jak and cdk2 protein kinases |
| BRPI0407384A (pt) | 2003-02-14 | 2006-02-21 | Pfizer Prod Inc | piridinas-triazóis como compostos antiinflamatórios |
| US20050222171A1 (en) | 2004-01-22 | 2005-10-06 | Guido Bold | Organic compounds |
| EP2360474B1 (en) | 2004-06-21 | 2013-07-24 | Galapagos N.V. | Methods and means for treatment of osteoarthritis |
| WO2006018735A2 (en) | 2004-08-18 | 2006-02-23 | Pharmacia & Upjohn Company Llc | Triazolopyridine compounds |
| MX2007004179A (es) | 2004-10-07 | 2007-06-07 | Warner Lambert Co | Derivados de triazolpiridina como agentes antibacterianos. |
| GB0515026D0 (en) | 2005-07-21 | 2005-08-31 | Novartis Ag | Organic compounds |
| BRPI0716239A2 (pt) * | 2006-08-30 | 2013-08-13 | Cellzome Ltd | derivados de triazol como inibidores de cinase |
| TW200904816A (en) | 2007-06-05 | 2009-02-01 | Takeda Pharmaceutical | Fused heterocycle derivatives and use thereof |
| EP2178868A1 (en) | 2007-07-18 | 2010-04-28 | Novartis Ag | Bicyclic heteroaryl compounds and their use as kinase inhibitors |
| WO2009017954A1 (en) * | 2007-08-01 | 2009-02-05 | Phenomix Corporation | Inhibitors of jak2 kinase |
| MX2010002312A (es) | 2007-08-31 | 2010-03-18 | Merck Serono Sa | Compuestos de triazolopiridina y su uso como inhibidores de cinasa reguladora de señal de apoptosis. |
| GB0719803D0 (en) * | 2007-10-10 | 2007-11-21 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| US20090217316A1 (en) * | 2008-02-22 | 2009-08-27 | Binita Gupta | Systems and Methods for Advertising Insertion Notification in a Real-Time Streaming Media Service |
| PE20110063A1 (es) | 2008-06-20 | 2011-02-16 | Genentech Inc | DERIVADOS DE [1, 2, 4]TRIAZOLO[1, 5-a]PIRIDINA COMO INHIBIDORES DE JAK |
| WO2010010187A1 (en) | 2008-07-25 | 2010-01-28 | Galapagos Nv | Novel compounds useful for the treatment of degenerative and inflammatory diseases |
| WO2010010186A1 (en) | 2008-07-25 | 2010-01-28 | Galapagos Nv | Novel compounds useful for the treatment of degenerative and inflammatory diseases |
| JO3041B1 (ar) | 2008-07-25 | 2016-09-05 | Galapagos Nv | مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية |
| WO2010010184A1 (en) | 2008-07-25 | 2010-01-28 | Galapagos Nv | [1, 2, 4] triazolo [1, 5-a] pyridines as jak inhibitors |
| WO2010010189A1 (en) | 2008-07-25 | 2010-01-28 | Galapagos Nv | Novel compounds useful for the treatment of degenerative and inflammatory diseases |
| WO2010010188A1 (en) | 2008-07-25 | 2010-01-28 | Galapagos Nv | Novel compounds useful for the treatment of degenerative and inflammatory diseases. |
| WO2010141796A2 (en) | 2009-06-05 | 2010-12-09 | Cephalon, Inc. | PREPARATION AND USES OF 1,2,4-TRIAZOLO [1,5a] PYRIDINE DERIVATIVES |
| TWI462920B (zh) | 2009-06-26 | 2014-12-01 | 葛萊伯格有限公司 | 用於治療退化性及發炎疾病之新穎化合物 |
| JO3030B1 (ar) | 2009-06-26 | 2016-09-05 | Galapagos Nv | مركب جديد مفيد لمعالجة الامراض التنكسية والالتهابات |
-
2010
- 2010-05-31 JO JOP/2010/0179A patent/JO3030B1/ar active
- 2010-06-23 TW TW99120587A patent/TWI469981B/zh not_active IP Right Cessation
- 2010-06-24 AR ARP100102236A patent/AR077221A1/es active IP Right Grant
- 2010-06-25 NZ NZ596836A patent/NZ596836A/xx not_active IP Right Cessation
- 2010-06-25 HR HRP20141057AT patent/HRP20141057T1/hr unknown
- 2010-06-25 PT PT107286486T patent/PT2445912E/pt unknown
- 2010-06-25 HU HUE14175887A patent/HUE034205T2/en unknown
- 2010-06-25 ES ES10728648.6T patent/ES2519170T3/es active Active
- 2010-06-25 KR KR1020127002060A patent/KR101712561B1/ko not_active Expired - Fee Related
- 2010-06-25 PE PE2011002144A patent/PE20120494A1/es active IP Right Grant
- 2010-06-25 DK DK10728648.6T patent/DK2445912T3/da active
- 2010-06-25 SG SG2011096179A patent/SG177359A1/en unknown
- 2010-06-25 UY UY0001032741A patent/UY32741A/es not_active Application Discontinuation
- 2010-06-25 MA MA34555A patent/MA33447B1/fr unknown
- 2010-06-25 EP EP14175887.0A patent/EP2792677B1/en active Active
- 2010-06-25 CN CN201080028413.0A patent/CN102459261B/zh active Active
- 2010-06-25 JP JP2012516762A patent/JP5486084B2/ja active Active
- 2010-06-25 PT PT141758870T patent/PT2792677T/pt unknown
- 2010-06-25 AU AU2010264635A patent/AU2010264635B2/en not_active Ceased
- 2010-06-25 SM SM20170333T patent/SMT201700333T1/it unknown
- 2010-06-25 MX MX2011013451A patent/MX2011013451A/es active IP Right Grant
- 2010-06-25 LT LTEP14175887.0T patent/LT2792677T/lt unknown
- 2010-06-25 BR BRPI1014759A patent/BRPI1014759A2/pt active Search and Examination
- 2010-06-25 ME MEP-2014-132A patent/ME01916B/me unknown
- 2010-06-25 ES ES14175887.0T patent/ES2634325T3/es active Active
- 2010-06-25 PL PL10728648T patent/PL2445912T3/pl unknown
- 2010-06-25 CA CA2765988A patent/CA2765988C/en not_active Expired - Fee Related
- 2010-06-25 EA EA201270076A patent/EA020111B1/ru not_active IP Right Cessation
- 2010-06-25 SI SI201031494T patent/SI2792677T1/sl unknown
- 2010-06-25 DK DK14175887.0T patent/DK2792677T3/en active
- 2010-06-25 SI SI201030775T patent/SI2445912T1/sl unknown
- 2010-06-25 WO PCT/EP2010/059067 patent/WO2010149771A1/en not_active Ceased
- 2010-06-25 US US12/823,682 patent/US8796457B2/en active Active
- 2010-06-25 EP EP10728648.6A patent/EP2445912B1/en active Active
- 2010-06-25 RS RS20140614A patent/RS53617B1/sr unknown
- 2010-06-25 PL PL14175887T patent/PL2792677T3/pl unknown
-
2011
- 2011-11-27 IL IL216618A patent/IL216618A/en not_active IP Right Cessation
- 2011-12-06 DO DO2011000378A patent/DOP2011000378A/es unknown
- 2011-12-14 CR CR20110673A patent/CR20110673A/es unknown
- 2011-12-22 ZA ZA2011/09502A patent/ZA201109502B/en unknown
- 2011-12-22 CL CL2011003276A patent/CL2011003276A1/es unknown
-
2012
- 2012-01-16 CO CO12005375A patent/CO6491039A2/es active IP Right Grant
-
2014
- 2014-08-04 US US14/451,127 patent/US9505754B2/en active Active
- 2014-11-10 SM SM201400169T patent/SMT201400169B/xx unknown
-
2017
- 2017-07-04 HR HRP20171024TT patent/HRP20171024T1/hr unknown
- 2017-07-24 CY CY20171100784T patent/CY1119711T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR077221A1 (es) | {5-[4-(3,3-dimetil-azetidina-1-carbonil)-fenil]-[1,2,4]triazolo[1,5-a]piridin-2-il} amida del acido ciclopropanocarboxilico inhibidor de quinasas janus(jak), en particular jak1, composiciones farmaceuticas que lo contienen y uso de los mismos para tratar afecciones inflamatorias, autoinmunes y proli | |
| AR077220A1 (es) | {5-[4-(1,1-dioxo-1-tiomorfolin-4-ilmetil)-fenil]-[1,2,4]triazolo[1,5-a]piridin-2-il} amida del acido ciclopropanocarboxilico inhibidor de quinasas janus(jak), composiciones farmaceuticas que lo contienen y uso de los mismos para tratar afecciones inflamatorias, autoinmunes y proliferativas. | |
| PE20150187A1 (es) | Aminotriazolopiridina para uso en tratamiento de inflamacion y composiciones farmaceuticas de la misma | |
| CO6551708A2 (es) | Procedimiento para la preparaci´n de {4.6- diamino-2-[1-(2- fluorobencil)-1h- pirazolo[3.4-b] piridin -3-il-]pirimidin -5-il} metilcarbamato de metilo y su purificación para su uso como principio famacéutico | |
| GEP20217242B (en) | Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors | |
| HN2010002121A (es) | 2,6-diamino-pirimidin-5-il-carboxamidas como inhibidores de syk o jak | |
| PE20211782A1 (es) | Compuestos de 5-cloro-2-difluorometoxifenil pirazolopirimidina, composiciones y metodos de uso de los mismos | |
| CL2011002115A1 (es) | Compuestos derivados de 5-fenil-1h-piridin-2-ona y 5-fenil-pirazin-2-ona, inhibidores de la tirosina-quinasa de bruton (btk); proceso de preparación de los compuestos, compuesto intermediario, composición farmacéutica y uso en el tratamiento de enfermedades inflamatorias y/o autoinmunes. | |
| MX355653B (es) | Compuesto novedoso util para el tratamiento de enfermedades degenerativas e inflamatorias. | |
| EA201490807A1 (ru) | Новые замещенные имидазопиримидины как модуляторы рецептора gpbar1 | |
| CO6660514A2 (es) | Derivados de ácido 2 quinolinil acético como compuestos antivirales del vih | |
| CO6602133A2 (es) | Derivados de i,idazo(1,2-a)pirazina y su uso para la prevencion o tratamiento de trastornos y enfermedades neurologicas, siquiatricas y metabolicas | |
| EA201791274A1 (ru) | ЗАМЕЩЕННЫЕ ПИПЕРИДИНОМ ПРОИЗВОДНЫЕ ПИРАЗОЛО[1,5-a]ПИРИМИДИНА С ИНГИБИРУЮЩЕЙ АКТИВНОСТЬЮ В ОТНОШЕНИИ РЕПЛИКАЦИИ РЕСПИРАТОРНО-СИНЦИТИАЛЬНОГО ВИРУСА (RSV) | |
| EA201591804A1 (ru) | Производные 2-((4-амино-3-(3-фтор-5-гидроксифенил)-1h-пиразоло[3,4-d]пиримидин-1-ил)метил)-3-(2-(трифторметил)бензил)хиназолин-4(3h)-она и их применение в качестве ингибиторов фосфоинозитид-3-киназы | |
| BR112014001665A2 (pt) | compostos de 2,3-di-hidroimidazo[1,2-c]pirimidin-5(1h)-ona utilizados como inibidores de lp-plaz | |
| MX374105B (es) | Compuestos azatricíclicos como inhibidores de tirosinas quinasas (jak) y el uso de los mismos en el tratamiento de enfermedades autoinmunes, inflamatorias y alérgicas. | |
| CO2020006789A2 (es) | Procedimiento para la preparación de (3s)-3-(4-cloro-3-{[(2s,3r)-2-(4-clorofenil)-4,4,4-trifluor-3-metilbutanoil]amino}fenil)-3-ácido ciclopropilpropanoico y su forma cristalina para uso como principio activo farmacéutico | |
| CL2011003076A1 (es) | Compuestos derivados de amidas del acido 6,7-dihidro-5h-imidazo[1,2-a]imidazol-3-carboxilico; composicion farmaceutica que los comprende; y su uso como inhibidores de la interaccion de las icam con las leucointegrinas y como antagonistas de lfa-1 para tratar una inflamacion o una afeccion inflamatoria tal como infarto al miocardio, accidente cerebrovascular, psoriasis, tiroiditis autoinmunitaria, enfermedad de crohn. | |
| UY33010A (es) | Compuestos de pirazina fusionados como sus sales, útiles para el tratamiento de enfermedades degenerativas e inflamatorias | |
| IN2013MU02611A (es) | ||
| UY30386A1 (es) | Compuestos de amida del acido 3-amino-tieno(2,3b(beta)piridina-2- carboxilico sustituido, procesos para su preparacion y usos de los mismos | |
| ECSP10010663A (es) | Compuestos de pirazina fusionados utiles para el tratamiento de enfermedades degenarativas e inflamatorias | |
| PL410363A1 (pl) | 3-(4-Nitrofenylo)-7,8-dihydroimidazo[2,1-c][1,2,4] triazyn-4(6H)-ony podstawione mono- lub dichlorofenylem, sposób ich otrzymywania i zastosowanie medyczne |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |